By IANS,
Mumbai : Japanese pharma major Daiichi Sankyo will soon have its presence in the Indian medicine market through a drug for people suffering from hypertension.
A co-promotion deal has been inked in Mumbai between the Indian pharmaceutical firm GlaxoSmithKline (GSK) Pharma and the Japanese firm’s subsidiary, Daiichi Sankyo India Pharma Ltd (DSIN) for marketing the drug Olmesartan Medoxomil and its combination products.
A GSK spokesperson said Wednesday that Olmesartan, an original research product of Daiichi Sankyo, is at present available in over 50 countries.
“This agreement, incidentally, comes in the wake of GSK’s in-licensing agreement signed last week for the anti-fungal drug Micafungin,” said Hasit Joshipura, GSK managing director.
DSIN president V. Vijayendran said the arrangement meets the requirements of both the organisations in the cardiology segment, adding: “the entry of DSIN not only paves the way for the introduction of several other research products in India, but also helps in enabling the companies to leverage their strengths to meet the needs of Indian population.”
GSK vice-president Ravi Limaye said Olmesartan will help their firm make a strong entry into the cardio-vascular therapeutic segment, which “is the fastest growing segment in the country”.